The Australian medical sector is excited with the emergence of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing impressive results in early trials for treating obesity. This medication https://bookmarksusa.com/story21847110/retatrutide-australia-a-emerging-prospect-for-weight-loss